DoP takes measures to mandatorily revise ceiling prices of drugs every five years
Amends Para 18(i) of DPCO 2013 as per a notification issued on August 12, 2021
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
DPCO 2013
AstraZeneca Pharma India files writ petition in Delhi High Court against NPPA demand notice
The notice of demand alleges that the company has overcharged about Rs 157.38 crore from March 8, 2019 to January 31, 2021, for…
Encourage members to adopt IPDMS: NPPA to pharma associations
The authority has also requested pharma associations to provide information regarding member companies that have already…
DoP asks NPPA to review, verify Bharat Serum and Vaccine’s request of revising ceiling price…
The company submitted its application expressing that the NPPA has erred in fixing the ceiling price of formulation
NLEM 2020: Should patented drugs be included in it?
At the National Consultation Stakeholders meeting held in August for the revision of NLEM 2015, industry stakeholders requested…
NPPA to fully automate ecosystem for applications
Also outlines timelines for disposal of received applications
NPPA fixes retail prices of 30 formulations, rejects four applications
Two applications each of Micro Laboratories and Sun Pharma have been deferred by the authority
NPPA rejects IPA request for upward price revision of five per cent on all drugs
According to DEA analysis concluded that some spike in import prices of certain APIs have been witnessed in the post-COVID-19…
NPPA fixes retail prices for 14 formulations
The fixed formulations are used to treat diabetes, hypertension, cholesterol, women’s health and mental health disorders
Industry recommends changes in draft guidelines for discontinuation of scheduled formulations
Seek amendments in para 3 and Para 19 to the DPCO 2013